Investigation of the effects of magnesium orotate in a model of primary generalized seizures

Objective: to investigate the anticonvulsant and neuroprotective effects of magnesium orotate in a rat thiosemicarbazide model of seizures in rats.

Material and methods. The investigation was conducted in 112 male albino rats weighing 200 g, in which severe clonic-tonic seizures weresimulated by the convulsant thiosemicarbazide. The anticonvulsant effects against of thiosemicarbazide-induced seizures were evaluated in the following drugs: gabapentin; a combination of gabapentin + magnesium orotate; sodium valproate; a combination of sodium valproate + magnesium orotate; and magnesium orotate. The neurological status, characteristics of seizures, survival rates, body weight, and plasma and red blood cell magnesium concentrations were compared. After completing the animal experiment, the animals were euthanized and the histological characteristics of their brains and nerves were analyzed.

Results. Magnesium orotate was ascertained to reduce the severity and duration of thiosemicarbazide-induced seizures, to increase animal survival rates, and to potentiate the anticonvulsant action of gabapentin and sodium valproate. The neurohistological findings showed that the used model of seizures led to ischemic brain damage.

Conclusion. It has been concluded that magnesium orotate minimized the level of ischemic damage to nerve cells and contributed to restoration of the morphology of brain tissues after thiosemicarbazide administration.

1. Громова ОА. Магний и пиридоксин: основы знаний. Москва: ПротоТип; 2006. 234 с. [Gromova OA. Magnii i piridoksin: osnovy znanii [Magnesium and pyridoxine: basic knowledge]. Moscow: ProtoTip; 2006. 234 p.].

2. Торшин ИЮ, Громова ОА. Экспертный анализ данных в молекулярной фармакологии. Москва: МЦНМО; 2012. 684 c. [Torshin IYu, Gromova OA. Ekspertnyi analiz dannykh v molekulyarnoi farmakologii [Expert data analysis in molecular pharmacology]. Moscow: MTsNMO; 2012. 684 p.].

3. Хабриев РУ, редактор. Руководство по экспериментальному (доклиническому) изучению новых лекарственных веществ. Москва: Медицина; 2005. С. 281-9. [Khabriev RU, editor. Rukovodstvo po eksperimental'nomu (doklinicheskomu) izucheniyu novykh lekarstvennykh veshchestv [Manual on experimental (preclinical) study of new pharmaceutical substances]. Moscow: Meditsina; 2005. P. 281-9.].

4. Селянина НВ. Мозговой нейротрофический фактор как прогностический критерий развития когнитивных нарушений у больных острой черепно-мозговой травмой. Медицинский альманах. 2013;(1):127-9. [Selyanina NV. Brain-derived neurotrophic factor as a prognostic criterion for the development of cognitive impairment in patients with acute traumatic brain injury. Meditsinskii al'manakh. 2013;(1):127-9. (in Russ.)].

5. Селянина НВ, Каракулова ЮВ. Активация репаративных процессов в остром периоде черепно-мозговой травмы под влиянием нейротрофической терапии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(5):46-9. [Selyanina NV, Karakulova YuV. Activation of reparative processes in the acute period of traumatic brain injury under the influence of neurotrophic therapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(5):46-9. (in Russ.)].

6. Torshin IY, Gromova OA. Magnesium and Pyridoxine: Fundamental Studies and Clinical Practice. New York: Nova Science Publishers; 2011.